Breaking News
Investing Pro 0
Extended Sale! Save on premium data with Claim 60% OFF

Nuformix delighted as NXP004 testing exceeds the company’s expectations

Published Dec 20, 2022 08:31 Updated Dec 20, 2022 08:40
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. Nuformix delighted as NXP004 testing exceeds the company’s expectations
 
NFXN
0.00%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Proactive Investors - Nuformix PLC has updated investors on its NXP004 programme which is developing novel forms of AstraZeneca’s Olaparib (Lynparza®) cancer drug.

Lynparza generated US$2.7bn of sales in 2021 though has presented challenges historically in terms of "pill burden" and low olaprib bioavailability, the company noted, and, it has so far filed two patent applications covering novel forms of olaparib with the potential of protection out to 2041.

These novel forms of Olaparib have undergone tests which have shown enhanced dissolution of the drug, compared to dissolution, and the company today highlighted these positive results.

"I'm delighted with the results of the head-to-head dissolution studies, which exceeded my expectations and have demonstrated first-time that the lead NXP004 cocrystals offer significant scope for enhanced performance versus Lynparza®, for which biorelevant dissolution data is not in the public domain,” said executive director Dr Dan Gooding.

“The NXP004 cocrystals studied demonstrate some of the best dissolution performance I've seen from application of the technology - a step-change in dissolution performance, yet they appear to lack any of the common drawbacks that can hamper development of cocrystal-based products, which is surprising.

“These new data strongly support progression of the programme and we will now look to translate these enhancements into an in-vivo setting, which if successful will position the company well for commencing partnering discussions with multiple potential partners identified."

Nuformix told investors it will now look at the design of suitable pre-clinical pharmacokinetic models to further investigate and validate NXP004's potential for enhancing the oral absorption of Olaparib, ahead of the commencement of talks with multiple potential commercialisation partners.

Read more on Proactive Investors UK

Disclaimer

Nuformix delighted as NXP004 testing exceeds the company’s expectations
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email